Health conditions
-
Prevalence rates for 10 chronic disorders at various FT4, TSH and FT3 levels
Which FT3, FT4 and TSH levels have the highest and lowest prevalence rates for 10 common health disorders? Hypertension Hyperlipidemia (high cholesterol) Depression Diabetes Coronary artery disease Heart failure Atrial fibrillation Peripheral vascular disease Renal failure (kidney failure) Dementia Is high-normal TSH and low FT3 associated with one condition, while high-normal FT4 and low or…
-
Anderson, 2020: Thyroid hormones and atrial fibrillation
Atrial fibrillation is a cardiac rhythm disorder that significantly elevates the risk of stroke as well as stroke severity. Thyroid hormone excess caused by hyperthyroidism is often named as one of the risk factors for atrial fibrillation. However, it does not require excess thyroid hormone above the reference range to elevate risk of atrial fibrillation.…
-
Acella NP Thyroid recall: maternal risk inflated
Acella, the makers of NP Thyroid, issued a voluntary recall notice on May 22, 2020. This is part 2 of a two-part series reviewing the drug recall notice’s statements and the science behind them. [Part 1: Acella NP Thyroid recall: Ethical yet low-risk] We should applaud Acella for being so conscientious about the exact amounts…
-
Questions about thyroid and COVID-19 risk
This is not just another blog post that tries to answer questions with authoritative statements about coronavirus from the World Health Organization. This blog post is about ASKING good questions and thinking critically about how questions are being answered. Our thyroid patient community has been asking, and many voices are trying to answer, this general…
-
Think twice about cancelling patient-pay Reverse T3 tests
At the end of January 2020, Alberta Precision Laboratories established a new policy of cancelling patient-pay Reverse T3 (RT3) tests on standard laboratory test orders. One memo in circulation explains the justifications based on RT3 silence in the 2012 and 2014 thyroid clinical guidelines. The memo was issued by Dr. Hossein Sadrzadeh, Section Chief, Clinical…